[go: up one dir, main page]

WO2004019901A3 - Sustained release pharmaceutical composition - Google Patents

Sustained release pharmaceutical composition Download PDF

Info

Publication number
WO2004019901A3
WO2004019901A3 PCT/IB2003/003602 IB0303602W WO2004019901A3 WO 2004019901 A3 WO2004019901 A3 WO 2004019901A3 IB 0303602 W IB0303602 W IB 0303602W WO 2004019901 A3 WO2004019901 A3 WO 2004019901A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
sustained release
release pharmaceutical
lactam antibiotic
beta lactam
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2003/003602
Other languages
French (fr)
Other versions
WO2004019901A2 (en
Inventor
Rajesh Suresh Kshirsagar
Sampath Kumar Devarajan
Kour Chand Jindal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orchid Pharma Ltd
Original Assignee
Orchid Chemicals and Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orchid Chemicals and Pharmaceuticals Ltd filed Critical Orchid Chemicals and Pharmaceuticals Ltd
Priority to AU2003260803A priority Critical patent/AU2003260803A1/en
Publication of WO2004019901A2 publication Critical patent/WO2004019901A2/en
Anticipated expiration legal-status Critical
Publication of WO2004019901A3 publication Critical patent/WO2004019901A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

The present invention relates to a sustained release oral pharmaceutical composition, having a beta lactam antibiotic or their pharmaceutically acceptable salts, hydrates or esters in a polymer mixture such that the beta lactam antibiotic is released over an extended period, suitable for once or twice daily oral administration. The invention preferably relates to a sustained release pharmaceutical composition of a beta lactam antibiotic having gelling tendency when in contact with the gastrointestinal fluids. The invention more preferably relates to sustained release pharmaceutical composition of prodrugs of cefpodoxime and cefuroxime such as cefpodoxime proxetil and cefuroxime axetil.
PCT/IB2003/003602 2002-08-30 2003-08-29 Sustained release pharmaceutical composition Ceased WO2004019901A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003260803A AU2003260803A1 (en) 2002-08-30 2003-08-29 Sustained release pharmaceutical composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN640CH2002 2002-08-30
IN640/MAS/2002 2002-08-30

Publications (2)

Publication Number Publication Date
WO2004019901A2 WO2004019901A2 (en) 2004-03-11
WO2004019901A3 true WO2004019901A3 (en) 2005-05-06

Family

ID=34509340

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/003602 Ceased WO2004019901A2 (en) 2002-08-30 2003-08-29 Sustained release pharmaceutical composition

Country Status (2)

Country Link
AU (1) AU2003260803A1 (en)
WO (1) WO2004019901A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230454B1 (en) * 1998-11-02 2016-07-28 Alkermes Pharma Ireland Limited Multiparticulate modified release composition of methylphenidate
WO2004105728A2 (en) * 2003-05-27 2004-12-09 Ranbaxy Laboratories Limited Solid dispersions of cefpodoxime proxetil and processes for their preparation
BR0318535A (en) * 2003-09-30 2006-09-12 Lupin Ltd pharmaceutical composition for controlled drug delivery, process for preparing a pharmaceutical composition and controlled release composition
BRPI0506710A (en) * 2004-01-06 2007-05-02 Panacea Biotec Ltd controlled release pharmaceutical compositions
GB0400971D0 (en) * 2004-01-16 2004-02-18 Sandoz Ag Pharmaceutical compositions
EP1681050A1 (en) * 2005-01-13 2006-07-19 Strides Arcolab Limited Dispersible sustained release pharmaceutical compositions
DE102005019458A1 (en) * 2005-04-25 2006-10-26 Grünenthal GmbH Composition, useful in the preparation of pellets and the multi-particular-presentation form, comprises cefuroximaxetil and carrageenan of the group of lambda carrageenan, tau carrageenan and kappa carrageenan
WO2008057058A1 (en) * 2006-11-10 2008-05-15 Nobel Ilac Sanayii Ve Ticaret As Oral pharmaceutical compositions
BRPI0718637B8 (en) * 2006-11-13 2016-06-07 Basf Se preparation of agrochemical active ingredients that are poorly soluble in water, process to combat unwanted mite or insect infestation and process to combat unwanted plant growth
CN102028669A (en) * 2010-10-27 2011-04-27 北京华禧联合科技发展有限公司 Slow release preparation of cefcapene pivoxil hydrochloride and preparation method thereof
WO2013109205A1 (en) * 2012-01-18 2013-07-25 Mahmut Bilgic Pharmaceutical tablet formulations comprising cefetamet
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
US9320740B2 (en) 2013-03-15 2016-04-26 Merck Sharp & Dohme Corp. Ceftolozane-tazobactam pharmaceutical compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
RU2017121505A (en) * 2014-12-01 2019-01-09 Сан Фармасьютикал Индастриз Лимитед COMPOSITION OF CEFPODOXYM PROXETYL WITH PROLONGED RELEASE
CN104434875B (en) * 2014-12-26 2017-08-01 华北制药河北华民药业有限责任公司 A kind of Cefaclor Capsules and preparation method thereof
CN107569466A (en) * 2017-09-17 2018-01-12 石家庄四药有限公司 Cefuroxime axetil pharmaceutical composition prepared by a kind of direct compression method
CN112023032B (en) * 2020-09-14 2022-03-18 广东鼎信医药科技有限公司 Pharmaceutical composition containing digestive enzyme and preparation method thereof
CN113908133B (en) * 2021-11-29 2023-11-03 河南省儿童医院郑州儿童医院 Cefixime sustained release tablet and preparation method thereof
TW202513040A (en) * 2023-09-01 2025-04-01 瑞士商赫孚孟拉羅股份公司 Novel methods for preparing semi-solid compositions and uses thereof
CN117243913B (en) * 2023-10-24 2024-09-17 国药集团致君（深圳）制药有限公司 Cefaclor sustained-release composition and preparation method thereof
CN120732800B (en) * 2025-08-19 2025-12-02 湖南恒昌医药集团股份有限公司 Ceftoranil sustained-release tablets and their preparation method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900247A (en) * 1995-12-29 1999-05-04 Adir Et Compagnie Mucoadhesive pharmaceutical composition for the controlled release of active principles
WO2000030647A1 (en) * 1998-11-26 2000-06-02 Biochemie Gesellschaft M.B.H. Compositions comprising cefuroxime axetil
WO2001000177A1 (en) * 1999-06-29 2001-01-04 Micio Pharma Chemical Aktiengesellschaft Retard formulation of amoxicillin for oral administration

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900247A (en) * 1995-12-29 1999-05-04 Adir Et Compagnie Mucoadhesive pharmaceutical composition for the controlled release of active principles
WO2000030647A1 (en) * 1998-11-26 2000-06-02 Biochemie Gesellschaft M.B.H. Compositions comprising cefuroxime axetil
WO2001000177A1 (en) * 1999-06-29 2001-01-04 Micio Pharma Chemical Aktiengesellschaft Retard formulation of amoxicillin for oral administration

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHANDY T ET AL: "Chitosan matrix for oral sustained delivery of ampicillin", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 14, no. 12, 1993, pages 939 - 944, XP002277124, ISSN: 0142-9612 *
DHOPESHWARKAR V ET AL: "DEVELOPMENT OF AN ORAL SUSTAINED-RELEASE ANTIBIOTIC MATRIX TABLET USING IN-VITRO/IN-VIVO CORRELATIONS", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, NEW YORK, NY, US, vol. 20, no. 11, 1994, pages 1851 - 1867, XP009025958, ISSN: 0363-9045 *

Also Published As

Publication number Publication date
AU2003260803A8 (en) 2004-03-19
WO2004019901A2 (en) 2004-03-11
AU2003260803A1 (en) 2004-03-19

Similar Documents

Publication Publication Date Title
WO2004019901A3 (en) Sustained release pharmaceutical composition
EP2298416A3 (en) Sustained-release tramadol formulations with 24-hour clinical efficacy
AU2003301957A1 (en) Administration of anti-inflammatory drugs into the central nervous system
WO2005107719A3 (en) Pharmaceutical composition comprising hydrophobic drug having improved solubility
NZ527867A (en) Oral pharmaceutical composition of cefpodoxime proxetil
WO2001043747A8 (en) Matrix tablet for prolonged release of trimetazidine after oral administration
WO2003087050A3 (en) Novel perindopril salt and pharmaceutical compositions containing same
NZ511900A (en) Sustained release matrix systems for highly soluble drugs
TR200201174T2 (en) Pharmaceutical compositions containing fluoroquinolone antibiotic medicine and xanthan gum.
AU2003226189A1 (en) Oral administration of epothilones
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
WO2005004915A3 (en) Compositions comprising meloxicam
AU2002321743A1 (en) Sustained release pharmaceutical composition of a cephalosporin antibiotic
WO2004111008A3 (en) Use of a compound of formula i for making a pharmaceutical composition
AU2003267602A1 (en) Polymer compositions for administration to animals
ATE410152T1 (en) THERAPEUTIC SYSTEM WITH AMOXICILLIN AND CLAVULANIC ACID
DK1461017T3 (en) Pharmaceutical composition for controlled release of a beta-lactam antibiotic
AU2003303367A1 (en) Compositions of benzoquinolizine carboxylic acid antibiotic drugs
WO2006122022A3 (en) Modified release famciclovir pharmaceutical compositions
MXPA05011521A (en) 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof.
CA2372238A1 (en) Polymorphs of a crystalline azabicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
WO2005065685A8 (en) Controlled release pharmaceutical composition comprising an acid-insoluble polymer and a bioadhesive polymer
MXPA04006888A (en) Prucalopride-n-oxide.
WO1999000112A8 (en) Sucralfate-containing composition and process for the preparation thereof
GEP20094649B (en) Orodispersible pharmaceutical composition of an antithrombotic compound

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP